首页> 美国卫生研究院文献>SAGE Choice >Hypofractionated Stereotactic Radiotherapy in Five Daily Fractions for Post-Operative Surgical Cavities in Brain Metastases Patients with and without Prior Whole Brain Radiation
【2h】

Hypofractionated Stereotactic Radiotherapy in Five Daily Fractions for Post-Operative Surgical Cavities in Brain Metastases Patients with and without Prior Whole Brain Radiation

机译:在有和没有事先全脑放射的脑转移患者中对手术后的手术腔进行每日五部分的超分割立体定向放射治疗

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Our purpose was to report efficacy of hypofractionated cavity stereotactic radiotherapy (HCSRT) in patients with and without prior whole brain radiotherapy (WBRT). 32 surgical cavities in 30 patients (20 patients/21 cavities had no prior WBRT and 10 patients/11 cavities had prior WBRT) were treated with image-guided linac stereotactic radiotherapy. 7 of the 10 prior WBRT patients had “resistant” local disease given prior surgery, post-operative WBRT and a re-operation, followed by salvage HCSRT. The clinical target volume was the post-surgical cavity, and a 2-mm margin applied as planning target volume. The median total dose was 30 Gy (range: 25-37.5 Gy) in 5 fractions. In the no prior and prior WBRT cohorts, the median follow-up was 9.7 months (range: 3.0-23.6) and 15.3 months (range: 2.9-39.7), the median survival was 23.6 months and 39.7 months, and the 1-year cavity local recurrence progression-free survival (LRFS) was 79 and 100%, respectively. At 18 months the LRFS dropped to 29% in the prior WBRT cohort. Grade 3 radiation necrosis occurred in 3 prior WBRT patients. We report favorable outcomes with HCSRT, and well selected patients with prior WBRT and “resistant” disease may have an extended survival favoring aggressive salvage HCSRT at a moderate risk of radiation necrosis.
机译:我们的目的是报告先行全脑放疗(WBRT)和不行全放疗的高分形腔立体定向放疗(HCSRT)的疗效。用图像引导直线加速器立体定向放射疗法治疗30例患者中的32个手术腔(20例21腔无WBRT,10例11腔有WBRT)。 10名先前的WBRT患者中,有7名在手术前,手术后WBRT和再次手术后再进行HCSRT抢救,出现了“耐药”局部疾病。临床目标体积为手术后腔,并以2 mm的余量作为计划目标体积。中位数总剂量为30个Gy(范围:25-37.5 Gy),分为5个部分。在之前和之前的WBRT队列中,中位随访时间分别为9.7个月(范围:3.0-23.6)和15.3个月(范围:2.9-39.7),中位生存期分别为23.6个月和39.7个月,以及1年腔局部无进展生存率(LRFS)分别为79%和100%。在之前的WBRT队列中,在18个月时,LRFS下降至29%。 3名先前的WBRT患者发生3级放射坏死。我们报告了HCSRT的良好疗效,并且经过精心挑选的先前WBRT和“耐药”疾病的患者可能具有延长生存期,有利于积极抢救HCSRT,而放射线坏死的风险中等。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号